Printer Friendly

NORTH AMERICAN BIOLOGICALS GAINS $2.5 MILLION IN ORDERS FOR HYPERIMMUNE PLASMA PRODUCTS FROM NEW CUSTOMER

 NORTH AMERICAN BIOLOGICALS GAINS $2.5 MILLION IN ORDERS
 FOR HYPERIMMUNE PLASMA PRODUCTS FROM NEW CUSTOMER
 MIAMI, March 12 /PRNewswire/ -- North American Biologicals, Inc. (NABI) (NASDAQ: NBIO) today announced it has received orders valued at $2.5 million from a major pharmaceutical manufacturer based in Switzerland. This new client has requested that during 1992 NABI provide certain hyperimmune plasmas to be used to produce Rho(D) immune globulin for the treatment and prevention of hemolytic disease of fetuses and newborns resulting from Rh incompatibility; rabies immune globulin for passive immunization subsequent to exposure to rabies; and Hepatits B immune globulin for passive immunization subsequent to exposure to Hepatitis B.
 NABI management, which earlier this week announced an expansion program to increase the company's plasma collection capacity, attributed the new orders to increasing worldwide demand for plasma and NABI's commitment to high quality. "We are delighted to have been chosen as the supplier for another major European client," said David J. Gury, president of NABI. "We see such orders as validating our strategy of focusing on the high value-added portion of our product portfolio, and ensuring stringent quality control of all our products."
 Hyperimmune plasma is the liquid portion of blood that contains certain specific antibodies. Such plasma can be obtained either by identifying donors who have already been exposed to the relevant antigens and have naturally developed the antibodies, or by selectively immunizing individuals to induce production of the antibodies. As the world's largest independent collector of plasma, NABI is uniquely positioned to supply hyperimmune plasma because it has access to a large base of donors each year, maintains a sophisticated laboratory to test for and identify such plasma, and has extensive experience in the hyperimmune plasma field. Through its network of 38 collection centers located across the country, NABI expects to collect more than one million liters of plasma this year.
 North American Biologicals, Inc., headquartered in Miami, is the world's largest independent provider of human blood plasma elements to the health care industry, the largest AIDS screening laboratory in the United States, and the leading supplier of control products used to ensure accuracy in blood testing laboratories.
 -0- 3/12/92
 /CONTACT: David J. Gury, president, or Alfred J. Fernandez, vice president of finance, of North American Biologicals, Inc., 305-628-0080; or Marcia A. Kean or Lori Martin of Feinstein Partners Inc., 617-577-8110/
 (NBIO) CO: North American Biologicals ST: Florida IN: MTC SU:


EG-DD -- NE002 -- 7659 03/12/92 09:21 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 12, 1992
Words:413
Previous Article:PHP HEALTHCARE WINS LAWSUIT
Next Article:PILLSBURY NAMES THOMAS A. DEBROWSKI SENIOR VICE PRESIDENT OF OPERATIONS
Topics:


Related Articles
NORTH AMERICAN BIOLOGICALS ARRANGES $19.5 MILLION IN FINANCING FOR ACQUISITION AND STOCK REPURCHASE
NORTH AMERICAN BIOLOGICALS COMPLETES $27 MILLION TRANSACTION
NORTH AMERICAN BIOLOGICALS, INC. TO SUPPLY HIVIG TO NATIONAL HEART, LUNG AND BLOOD INSTITUTE FOR CLINICAL TRIAL
NORTH AMERICAN BIOLOGICALS TO ACQUIRE MAJOR PLASMA COMPANY
NORTH AMERICAN BIOLOGICALS, INC. AWARDED $165 MILLION MULTI-YEAR PLASMA SUPPLY CONTRACT
/C O R R E C T I O N -- NORTH AMERICAN BIOLOGICALS, INC./(Correction Notice)
NORTH AMERICAN BIOLOGICALS, INC. REPORTS RECORD RESULTS FOR SECOND QUARTER 1995
NORTH AMERICAN BIOLOGICALS, INC. AND UNIVAX BIOLOGICS, INC. MERGER CLEARS FTC REVIEW
HEMASURE AND NOVO NORDISK SIGN HEADS OF AGREEMENT ON SALE OF NOVO NORDISK'S PLASMA PRODUCTS BUSINESS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters